Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Irreversible Electroporation (IRE) for Breast Cancer

NCT02340858 is registered in ClinicalTrials.gov with Fuda Cancer Hospital, Guangzhou as lead sponsor.

NCT NCT02340858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02340858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Irreversible Electroporation (IRE) for Breast Cancer
Lead sponsor
Fuda Cancer Hospital, Guangzhou
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2015
Completion date
January 1, 2021
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer